دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Inside This Issue
doi : 10.1016/S1936-8798(22)02019-2
Volume 15, Issue 22, 28 November 2022, Pages A11-A15
P2Y12 Inhibitor or Aspirin Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Network Meta-Analysis
Giuseppe Andò, MD, P HD, a Giulia Azzurra De Santis, MD,a Antonio Greco, MD,b Lorenzo Pistelli, MD, a Bruno Francaviglia, MD, b Davide Capodanno, MD, PH D, b Raffaele De Caterina, MD, P HD, c Piera Capranzano, MD, P HD
doi : 10.1016/j.jcin.2022.08.009
Volume 15, Issue 22, 28 November 2022, Pages 2239-2249
It is still unknown which antiplatelet monotherapy should be continued after a period of dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI).
SAPT After DAPT: Tailoring Platelet Inhibitor Therapy After PCI
Dean J. Kereiakes, MD
doi : 10.1016/j.jcin.2022.08.017
Volume 15, Issue 22, 28 November 2022, Pages 2250-2252
Platelet Reactivity and Clinical Outcomes After Drug-Eluting Stent Implantation: Results From the PTRG-DES Consortium
Seung-Jun Lee, MD, a, * Jung-Joon Cha, MD, b, * Young-Hoon Jeong, MD, c Sung-Jin Hong, MD, a Chul-Min Ahn, MD, a Jung-Sun Kim, MD,a Young-Guk Ko, MD, a Donghoon Choi, MD, a Myeong-Ki Hong, MD, a Yangsoo Jang, MD, d Hyung Joon Joo, MD, b Kiyuk Chang, MD, e Yongwhi Park, MD,f Young Bin Song, MD,g Sung Gyun Ahn, MD,h Jung-Won Suh, MD, i Sang Yup Lee, MD,c,j Jung Rae Cho, MD, k Ae-Young Her, MD,l Hyo-Soo Kim, MD,m Moo Hyun Kim, MD,n Eun-Seok Shin, MD,o Do-Sun Lim, MD, b Byeong-Keuk Kim, MD, a on behalf of the PTRG Investigators
doi : 10.1016/j.jcin.2022.09.007
Volume 15, Issue 22, 28 November 2022, Pages 2253-2265
The long-term prognostic implication of platelet reactivity after percutaneous coronary intervention (PCI) is not clearly known.
Platelet Reactivity Testing: East Meets West∗
Gregg W. Stone, MD, Anton Camaj, MD, MS
doi : 10.1016/j.jcin.2022.09.046
Volume 15, Issue 22, 28 November 2022, Pages 2266-2269
Ticagrelor vs Prasugrel in a Contemporary Real-World Cohort Undergoing Percutaneous Coronary Intervention
Anoop N. Koshy, MBBS, PHD, a,b Gennaro Giustino, MD, a Samantha Sartori, P HD, a Htoo Kyaw, MD,a Mayank Yadav, MD,a Zhongjie Zhang, MPH,a Amit Hooda, MD,a Ali Farooq, MD,a Parasuram Krishnamoorthy, MD, a Joseph M. Sweeny, MD, a Sahil Khera, MD, MPH,a Gregory W. Serrao, MD,a Raman Sharma, MD,a Javed Suleman, MD, a George Dangas, MD, P HD, a Annapoorna S. Kini, MD, a Roxana Mehran, MD,a,c Samin K. Sharma, MD
doi : 10.1016/j.jcin.2022.09.021
Volume 15, Issue 22, 28 November 2022, Pages 2270-2280
Potent P2Y12 agents such as ticagrelor and prasugrel are increasingly utilized across the clinical spectrum of patients undergoing percutaneous coronary intervention (PCI). There is a paucity of data supporting their use in a patient population inclusive of both acute coronary syndrome (ACS) and chronic coronary syndrome (CCS) patients.
Prasugrel and Ticagrelor Treatment Among Patients With ACS: Is There a Need for a New Randomized Trial?∗
Jochen Wöhrle, MD, Julia Seeger, MD
doi : 10.1016/j.jcin.2022.10.019
Volume 15, Issue 22, 28 November 2022, Pages 2281-2283
Use of the Limited Antegrade Subintimal Tracking Technique in Chronic Total Occlusion Percutaneous Coronary Intervention
Judit Karacsonyi, MD, P HD, a Spyridon Kostantinis, MD,a Bahadir Simsek, MD,a Khaldoon Alaswad, MD, b Dimitri Karmpaliotis, MD, PH D, c Ajay Kirtane, MD,d Farouc Jaffer, MD, P HD, e James W. Choi, MD, f Michalis Koutouzis, MD,g Ioannis Tsiafoutis, MD,g David E. Kandzari, MD, h Paul Poommipanit, MD,i Jaikirshan J. Khatri, MD, j Basem Elbarouni, MD,k Sevket Gorgulu, MD, l Ahmed ElGuindy, MD, m Nidal Abi Rafeh, MD,n Omer Goktekin, MD, o Imre Ungi, MD, P HD, p Bavana V. Rangan, BDS, MPH,a Yader Sandoval, MD,q Salman Allana, MD, r M. Nicholas Burke, MD,a Emmanouil S. Brilakis, MD, PHD
doi : 10.1016/j.jcin.2022.08.052
Volume 15, Issue 22, 28 November 2022, Pages 2284-2293
There are limited data on the limited antegrade subintimal tracking (LAST) technique for chronic total occlusion (CTO) percutaneous coronary intervention (PCI).
As the Word Says, “LAST Should Be the Last�∗
Antonio Colombo, MD,a,b Pier Pasquale Leone, MD, a,b,c Gabriele Gasparini, MD
doi : 10.1016/j.jcin.2022.09.028
Volume 15, Issue 22, 28 November 2022, Pages 2294-2296
Distal vs Conventional Radial Access for Coronary Angiography and/or Intervention: AÂ Meta-Analysis of Randomized Trials
Giuseppe Ferrante, MD, PHD, a,b Francesco Condello, MD, a Sunil V. Rao, MD,c Matteo Maurina, MD,a,b Sanjit Jolly, MD, MS C,d Giulio G. Stefanini, MD, PH D, MSC ,a,b Bernhard Reimers, MD, a,b Gianluigi Condorelli, MD, P HD, a,b Thierry Lefèvre, MD,e Samir B. Pancholy, MD, f,g Olivier Bertrand, MD, P HD, h Marco Valgimigli, MD, P HD i
doi : 10.1016/j.jcin.2022.09.006
Volume 15, Issue 22, 28 November 2022, Pages 2297-2311
Emerging evidence from randomized clinical trials (RCTs) comparing distal radial access (DRA) with conventional radial access (RA) is available.
Distal Radial Artery Access: Fad or New Frontier?∗
Matthew I. Tomey, MD, Jacqueline E. Tamis-Holland, MD
doi : 10.1016/j.jcin.2022.09.045
Volume 15, Issue 22, 28 November 2022, Pages 2312-2314
Supraventricular Arrhythmia Following Patent Foramen Ovale Percutaneous Closure
Paul Guedeney, MD, a Mikael Laredo, MD, a Michel Zeitouni, MD, PHD, a Marie Hauguel-Moreau, MD, b Thomas Wallet, MD,a Benjamin Elegamandji, MD, a Sonia Alamowitch, MD, PH D, c Sophie Crozier, MD,c Candice Sabben, MD,d Sandrine Deltour, MD, PHD, e Michaël Obadia, MD,d Nadia Benyounes, MD,f Jean-Philippe Collet, MD, P HD, a Stéphanie Rouanet, MS, g Nadjib Hammoudi, MD, PHD, a Johanne Silvain, MD, PHD, a Gilles Montalescot, MD, PH D
doi : 10.1016/j.jcin.2022.07.044
Volume 15, Issue 22, 28 November 2022, Pages 2315-2322
Atrial Fibrillation After Percutaneous PFOÂ Closure: Not So Rare After All
Suzanne J. Baron, MD, MSC
doi : 10.1016/j.jcin.2022.08.022
Volume 15, Issue 22, 28 November 2022, Pages 2323-2325
The Effect of Psychosocial Risk Factors on Outcomes After Aortic Valve Replacement
Paige Newell, MD,a,b Cheryl Zogg, PHD, MSPH, MHS, c Hugh Shirley, BS, a Jessica Feliz, MD, a,b Sameer Hirji, MD, MPH,a Morgan Harloff, MD,a Mariam Kerolos, BS, a Pinak Shah, MD, d Tsuyoshi Kaneko, MD
doi : 10.1016/j.jcin.2022.08.014
Volume 15, Issue 22, 28 November 2022, Pages 2326-2335
Psychosocial Fitness for Aortic Valve Replacement: Can Anxiety, Depression, and Postcode Influence the Outcomes?
Jaya Chandrasekhar, MBBS, MS, P HD
doi : 10.1016/j.jcin.2022.09.029
Volume 15, Issue 22, 28 November 2022, Pages 2336-2338
Transjugular Transcatheter Tricuspid Valve Replacement for Original Valve Regurgitation
Zhefeng Kang, MM,* Jun Shi, MD,* Lulu Liu, MD, Yingqiang Guo, MD
doi : 10.1016/j.jcin.2022.08.054
Volume 15, Issue 22, 28 November 2022, Pages 2339-2340
Intraprocedural Mapping of the Mitral Calcium for Positioning and Deployment of Transcatheter Valve–in–Mitral Annular Calcification
Francesca Romana Prandi, MD,a,b George D. Dangas, MD, PH D, a Annapoorna Kini, MD,a Francesco Romeo, MD, c Saman Suleman, MD, a Sahil Khera, MD, a Gilbert H.L. Tang, MD, MSC , MBA, d Samin Sharma, MD,a Stamatios Lerakis, MD, P HD
doi : 10.1016/j.jcin.2022.07.040
Volume 15, Issue 22, 28 November 2022, Pages 2341-2343
Giant Right Coronary Artery Pseudoaneurysm Exclusion With Atrial Septal Defect Closure Device Following Coronary Rupture
Radu Spînu, MD, Loic Belle, MD, Emmanuel Cassar, MD, Henry Bonnet, MD, Lionel Mangin, MD
doi : 10.1016/j.jcin.2022.09.024
Volume 15, Issue 22, 28 November 2022, Pages e231-e232
Balloon-Expandable Valve Implantation in a Systemic Tricuspid Valve With Annular Calcification Using 3D CT Overlay
Angelo Fabio d’Aiello, MD,a,b Federico De Marco, MD,c Paolo Ferrero, MD, a,b Giulia Pasqualin, MD, a,b Umberto Di Dedda, MD, d Alessandro Giamberti, MD, b,e Dina Mostafa Maria, MD, a,f Massimo Chessa, MD, P HD
doi : 10.1016/j.jcin.2022.08.055
Volume 15, Issue 22, 28 November 2022, Pages e233-e235
A Floating Coil
LucÃa Cobarro, MD, Guillermo Galeote, MD, PH D, Daniel Tébar, MD, Sandra Rosillo, MD, Alfonso Jurado-Román, MD, PHD, Santiago Jimenez-Valero, MD, Artemio GarcÃa-Escobar, MD, Silvio Vera, MD, Esteban López de Sá, MD, PHD, Raúl Moreno, MD, PHD
doi : 10.1016/j.jcin.2022.09.044
Volume 15, Issue 22, 28 November 2022, Pages e237-e238
Postintervention Imaging for Optimal Percutaneous Coronary Interventions
Nihat Kalay, MD Bulent Behlul Altunkeser, MD Sevket Gorgulu, MD
doi : 10.1016/j.jcin.2022.09.019
Volume 15, Issue 22, 28 November 2022, Page 2344
Reply: Postintervention Imaging for Optimal Percutaneous Coronary Interventions
Tara Neleman, BSc Frederik T.W. Groenland, MD *Joost Daemen, MD, PhD
doi : 10.1016/j.jcin.2022.09.058
Volume 15, Issue 22, 28 November 2022, Page 2345
Significant vs Severe Aortic Stenosis: The Rule of 4
*Amr E. Abbas, MD
doi : 10.1016/j.jcin.2022.09.016
Volume 15, Issue 22, 28 November 2022, Pages 2345-2347
Reply: Significant vs Severe Aortic Stenosis: The Rule of 4
Augustin Coisne, MD, PhD Andrea Scotti, MD Azeem Latib, MD Martin B. Leon, MD Juan F. Granada, MD
doi : 10.1016/j.jcin.2022.10.002
Volume 15, Issue 22, 28 November 2022, Page 2347
Percutaneous Coronary Revascularization in Patients Undergoing TAVR: A Different Entity or More of the Same?
Ricardo O. Escárcega, MD Mauricio G. Cohen, MD Moses Mathur, MD
doi : 10.1016/j.jcin.2022.09.030
Volume 15, Issue 22, 28 November 2022, Page 2348
Reply: Percutaneous Coronary Revascularization in Patients Undergoing TAVR: A Different Entity or More of the Same?
Lennert Minten, MD Johan Bennett, MD, PhD Christophe Dubois, MD, PhD
doi : 10.1016/j.jcin.2022.10.003
Volume 15, Issue 22, 28 November 2022, Pages 2348-2349
De Novo Left Main Spontaneous Coronary Artery Dissection: A Case Series
Rohit Samuel, MD Mesfer Alfadhel, MD Cameron McAlister, MD Thomas Nestelberger, MD Andrew Starovoytov, MD Johandra Argote Parolis, MD Tejana Grewal, MD Eve Aymong, MD *Jacqueline Saw, MD
doi : 10.1016/j.jcin.2022.09.052
Volume 15, Issue 22, 28 November 2022, Pages 2349-2351
